Release date: 2015-12-25 Just as there is no pair of shoes to satisfy everyone's feet, a drug can't be used for everyone. The empirical drug use and the uniform drug use mode will be gradually broken in the future, replaced by personalized medicine. At that time, precision medicine began to enter people's field of vision. At present, in the clinical field, precision medicine has involved non-invasive prenatal, assisted reproduction, monogenic diseases, newborn screening, individualized treatment of tumors, genetic tumor screening, cardiovascular screening, blood disease screening, etc. Treatment is considered by the industry to be the largest market in the future. Traditional medication mode will be changed For precision medicine, the industry has a variety of insights. According to Wu Bolin, a professor at Boston Children's Hospital affiliated with Harvard Medical School, precision medicine is derived from genomics, which refers to the application of genomics at the genetic and molecular levels and the various omics (proteomics, metabolomics, Performance genomics, etc.) to diagnose the cause or detect the target of treatment, so that the original "one size fits all" treatment plan may be transformed into an effective treatment for the individual cause. "Thousand people and one medicine" not only brings trouble to patients, but also causes waste of resources. It can become a consensus in the industry by saving individual medical costs through individualized genetic testing. The market expects that the global precision medical market will be nearly 60 billion US dollars in 2015, and the growth rate is expected to be 15% in the next five years, which is 3-4 times of the overall growth rate of the pharmaceutical industry. The growth rate of the genetic sequencing industry will exceed 20%. Currently in the world, the United States is in the first echelon of precision medicine. Earlier this year, Obama raised it to a national strategy and proposed to invest $215 million in the 2016 fiscal year to promote precision medical development. At the same time, relevant domestic policies are constantly being explored. In July of this year, the National Health and Family Planning Commission issued the "Technical Guidelines for Gene Detection of Drug Metabolizing Enzymes and Drug Targets (Trial)" and "Technical Guidelines for Tumor Individualized Treatment Testing (Trial)", which were interpreted by the market as the government's substantive development of genes. Detection and accurate medical signalling. In the "Technical Guidelines for Individualized Treatment of Tumors (Trial)", the competent authorities reaffirmed the efficacy and evaluation of drugs by detecting gene mutations, gene SNP typing, gene and protein expression status of biomarkers in biological samples of tumor patients. Prognosis, guide the practice of clinical individualized treatment, and recommend cancer patients to conduct genetic testing before treatment, and guide doctors to use drugs. "The future trend, the treatment of tumors must start with accurate calculations, and then have a precise diagnosis, and finally bring us a precise therapeutic effect." Mao Mao, senior vice president of Shanghai Pharmacy Kangde New Drug Development Co., Ltd. Predicted. Zhang Wei, a professor at Central South University who is one of the drafters of the above guidelines, said that precision medicine is not only for patients with diseases, but also for health prevention: for example, pharmacogenomics, that is, using the right dose at the right time, and also involving disease prediction, Prenatal diagnosis, neonatal genetic testing, etc. In the future, testing equipment may be as easy to carry as a small blood glucose meter, but from now on, it will take some time. Accurate medical treatment receives large capital injection From the perspective of drug research and development, the ideal precision medicine is to realize the treatment policy based on the patient's personal genomic information, and to grasp the individualized differences in the response of treatment or toxic side effects, and to optimize the treatment for each patient. With the improvement of sequencing technology and big data analysis capabilities, the number of companies involved in precision medicine is increasing. Idea Di Medical Technology Group was incorporated in Shanghai in 2010. The company focuses on three areas of precision tumor prevention, tumor precision treatment and new drug research and development. It is understood that Idea Di has established a unique large-scale primary tumor cell development platform and humanized tumor animal model platform with the support of hundreds of millions of funds in the first three rounds. Among them, the preclinical drug development platform for hepatobiliary tumors has been completed, and three preclinical compounds have been selected and will be clinically tested in the next one to two years. At present, the tumor genome has found 2,000 known and potential gene targets, and hundreds of tumor-driven genes have been confirmed, but not many target drug developments have been completed. Not long ago, I got the fourth round of financing. I have my own business model for cancer precision medicine, which is to expand the cancer prevention, diagnosis and new drug development business based on big data, and make a closed loop for cancer prevention and diagnosis to new drug development. "The advantage of closed-loop is that the links are closely linked. The development of new drugs guided by the reverse thinking of the patient's genome big data will greatly improve the success rate and reduce the development risk." Former FDA Drug Evaluation Center senior new drug reviewer, Idea Di Group Dr. Gong Zhaolong, CEO, explained. According to media reports, Dr. Xiong Lei, the founder of Idea Di, disclosed to the outside world that the financing purpose is to promote the promotion of tumor precision prevention, accelerate the national distribution of precision treatment business, and promote the preclinical development and clinical application of several existing tumor precision drugs. Increase the intensity of data construction. It can be seen that the idea of ​​Di is to take a multi-point attack from prevention, diagnosis and new drugs. In addition, the idea of ​​this round of financing to introduce Tasly. As the only strategic investment institution from the pharmaceutical field to date, Tasly has sent a senior investment consultant to serve as a director of Ideas. As a result, the two sides will reach a strategic partnership and jointly complete the development of precision drugs and drugs, or not only in speculation. There are many problems behind the hilarity "Obama's concept of precision medicine is out, the United States is still relatively calm, but China is showing a hot scene, all over the corners, even township hospitals claim to be precision medicine. Precision medicine centers have mushroomed, The industry does not talk about a few precise medical treatments, for fear that it is not understood to be scientific." Genetic biologist and academician of the Chinese Academy of Sciences He Lin recently at the "International Precision Medicine and Future Health Frontier Symposium" in Shanghai, for the current hot to hot precision The medical spilled a few minutes of cold water. He Lin pointed out that precision medicine should not be used in general and should not be abused. How to make the medication mode from the empirical medication (A can't, use B, B can't, then use C...) to personalize medication (for A, B, C) The steady transformation of the pattern of people's medications requires a cold thinking in practice rather than a “Great Leap Forward†input to truly contribute to health. Wu Berlin said that precision medicine brings development opportunities for genetic testing and genetic counseling, but not all projects are “higherâ€, the better, large, medium and small, and can be recognized by the people and the market. If there is a lot of data in a test report, looking beautiful, and there is no practical guidance value, finally failed to solve the problem for doctors and patients. Zhu Bin, chairman of Shanghai Baiao Technology Co., Ltd. also said that the content of the report should meet the clinical needs, but because there is no uniform standard, the reporting time and content of different institutions after testing have affected doctors and doctors to some extent. The patient's treatment time and plan, and even the doctor asked how to use the data. In addition, the reporter found in the interview that regarding precision medical treatment, there are still some products in the market with different prices, exaggerated effects, and eyeballs. Zhou Hongyu, an academician of the Chinese Academy of Engineering and director of the Institute of Clinical Pharmacology at Central South University, said that although the entry of capital has helped the development of precision medicine, the industry needs to calm down and stick to it in order to make this Huimin project healthy. development of. Recently, China's individualized medicine-accurate medical science industry alliance came into being. Many experts believe that there is still a lot of work in precision medicine that needs to be studied in depth to find more new biomarkers and to provide new treatments for those whose medical needs are not met. As the industry continues to push forward, there is still a need to address how to implement it, and it is not just at the technical level. Wu Bolin suggested that the principle of maturity and application of a genetic polymorphism related to complex diseases that has been confirmed by many independent studies requires a high-quality and standardized interpretation of the test results. Relevant high-level genetic counseling to assess the risk of the disease and the likely incidence of the disease in the individual, and to design a disease prevention and health management program for the individual. In addition, some industry insiders suggest that it is necessary to speed up the improvement of laboratory practices, data storage management, etc., and issues related to personal genetic information, data security supervision and ethics should also be taken seriously. (Source: Economic Information Daily) Source: Economic Reference Adult Non-Woven Fabrics Cover,Bacteria Protection Face Mask,3-layer Filter Protective Face Mask Dongguan Keyutai Mask Co., Ltd. , https://www.maskkytai.com